CBL-B checkpoint inhibitor (Jiangsu Simcere Pharma/Hainan Sparkle Therapeutics)

N/A

Report date: 2025/03/14 16:34:52

Base Information

Drug NameCBL-B checkpoint inhibitor (Jiangsu Simcere Pharma/Hainan Sparkle Therapeutics)
Drug Alias NameN/A
ClassificationBiologics
Mechanisms of ActionE3 ubiquitin-protein ligase CBL-B inhibitors
TargetsE3 ubiquitin-protein ligase CBL-B
Therapy Area/IndicationsMultiple MyelomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesJiangsu Simcere Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHainan Xiansheng Re Ming Pharmaceutical Co LtdJiangsu Simcere Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A